Clinical Trial Update: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating transarterial radioembolization with durvalumab and bevacizumab for unresectable hepatocellular carcinoma; status is active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING